Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but remained clinically effective: Were monoclonal antibodies against COVID-19 rejected too early?

{ 'indexed': {'date-parts': [[2024, 8, 13]], 'date-time': '2024-08-13T04:40:05Z', 'timestamp': 1723524005614}, 'reference-count': 12, 'publisher': 'Elsevier BV', 'issue': '9', 'license': [ { 'start': { 'date-parts': [[2024, 9, 1]], 'date-time': '2024-09-01T00:00:00Z', 'timestamp': 1725148800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2024, 9, 1]], 'date-time': '2024-09-01T00:00:00Z', 'timestamp': 1725148800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/legal/tdmrep-license'}, { 'start': { 'date-parts': [[2024, 7, 31]], 'date-time': '2024-07-31T00:00:00Z', 'timestamp': 1722384000000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0/'}], 'funder': [ { 'DOI': '10.13039/501100024075', 'name': 'Region of Southern Denmark', 'doi-asserted-by': 'publisher'}], 'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.es', 'clinicalkey.com.au', 'clinicalkey.com', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2024, 9]]}, 'DOI': '10.1016/j.jiph.2024.102512', 'type': 'journal-article', 'created': {'date-parts': [[2024, 8, 7]], 'date-time': '2024-08-07T02:24:28Z', 'timestamp': 1722997468000}, 'page': '102512', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but remained clinically ' 'effective: Were monoclonal antibodies against COVID-19 rejected too early?', 'prefix': '10.1016', 'volume': '17', 'author': [ {'given': 'Line Lundegaard', 'family': 'Bang', 'sequence': 'first', 'affiliation': []}, {'given': 'Lone Wulff', 'family': 'Madsen', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rune Micha', 'family': 'Pedersen', 'sequence': 'additional', 'affiliation': []}, {'given': 'Anna Christine', 'family': 'Nilsson', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-2189-9823', 'authenticated-orcid': False, 'given': 'Isik Somuncu', 'family': 'Johansen', 'sequence': 'additional', 'affiliation': []}, {'given': 'Thomas Emil', 'family': 'Andersen', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'issue': '2', 'key': '10.1016/j.jiph.2024.102512_bib1', 'doi-asserted-by': 'crossref', 'first-page': '315', 'DOI': '10.1016/j.jiph.2023.11.029', 'article-title': 'Real world effectiveness of sotrovimab in preventing COVID-19–related ' 'hospitalisation or death in patients infected with Omicron BA.2', 'volume': '17', 'author': 'Behzad', 'year': '2024', 'journal-title': 'J Infect Public Health'}, { 'issue': '1', 'key': '10.1016/j.jiph.2024.102512_bib2', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1007/s15010-023-02098-5', 'article-title': 'Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 ' 'infection during Omicron BA.2 subvariant predominance: a systematic ' 'literature review', 'volume': '52', 'author': 'Drysdale', 'year': '2024', 'journal-title': 'Infection'}, { 'key': '10.1016/j.jiph.2024.102512_bib3', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.ebiom.2022.104158', 'article-title': 'Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and ' 'BA.2 by convalescent and vaccine serum and monoclonal antibodies', 'volume': '82', 'author': 'Wilhelm', 'year': '2022', 'journal-title': 'eBioMedicine'}, { 'issue': '7917', 'key': '10.1016/j.jiph.2024.102512_bib4', 'doi-asserted-by': 'crossref', 'first-page': '119', 'DOI': '10.1038/s41586-022-04856-1', 'article-title': 'Characterization and antiviral susceptibility of SARS-CoV-2 Omicron ' 'BA.2', 'volume': '607', 'author': 'Uraki', 'year': '2022', 'journal-title': 'Nature'}, { 'issue': '6', 'key': '10.1016/j.jiph.2024.102512_bib5', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.heliyon.2023.e16664', 'article-title': 'Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 ' 'in a non-human primate model', 'volume': '9', 'author': 'Hérate', 'year': '2023', 'journal-title': 'Heliyon'}, { 'key': '10.1016/j.jiph.2024.102512_bib6', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.antiviral.2023.105638', 'article-title': 'Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in ' 'a hamster model', 'volume': '215', 'author': 'Driouich', 'year': '2023', 'journal-title': 'Antivir Res'}, { 'key': '10.1016/j.jiph.2024.102512_bib7', 'unstructured': 'Zhang A, Stacey HD, D’Agostino MR, Tugg Y, Marzok A, Miller MS. Beyond ' 'neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 ' 'infection. Nat Rev Immunol; 2022 [Internet] [cited 2023 Sep 13]; ' 'Available from: 〈https://www.nature.com/articles/s41577-022-00813-1〉.'}, { 'key': '10.1016/j.jiph.2024.102512_bib8', 'unstructured': 'Therapeutics and COVID-19: living guideline, 16 September 2022. Geneva: ' 'World Health Organization; 2022 (WHO/2019-nCoV/therapeutics/2022.5). ' 'Available from: ' 'https://iris.who.int/bitstream/handle/10665/362843/WHO-2019-nCoV-therapeutics-2022.5-eng.pdf.'}, { 'issue': '1', 'key': '10.1016/j.jiph.2024.102512_bib9', 'doi-asserted-by': 'crossref', 'first-page': '4545', 'DOI': '10.1038/s41467-023-40204-1', 'article-title': 'Monoclonal antibody levels and protection from COVID-19', 'volume': '14', 'author': 'Stadler', 'year': '2023', 'journal-title': 'Nat Commun'}, { 'issue': '753', 'key': '10.1016/j.jiph.2024.102512_bib10', 'doi-asserted-by': 'crossref', 'DOI': '10.1126/scitranslmed.ado2817', 'article-title': 'AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and ' 'is protective in hamsters and well tolerated in adults', 'volume': '16', 'author': 'Cai', 'year': '2024', 'journal-title': 'Sci Transl Med'}, { 'key': '10.1016/j.jiph.2024.102512_bib11', 'unstructured': 'SUPERNOVA Phase I.I.I. trial of sipavibart long-acting antibody met ' 'primary endpoints in preventing COVID-19 in immunocompromised patient ' 'population [Internet]. 2024 [cited 2024 Jul 8]. Available from: ' '〈https://www.astrazeneca.com/media-centre/press-releases/2024/supernova-trial-met-covid-19-prevention-endpoint.html〉.'}, { 'key': '10.1016/j.jiph.2024.102512_bib12', 'unstructured': 'F.D.A. (Food and Drug Administration). Fact sheet for patients, parents, ' 'and caregivers Emergency Use Authorization (EUA) of PEMGARDA ' '(pemivibart) for coronavirus disease 2019 (COVID-19) [Internet]. [cited ' '2024 Jul 15]. Available from: ' '〈https://www.fda.gov/media/177069/download〉.'}], 'container-title': 'Journal of Infection and Public Health', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1876034124002466?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S1876034124002466?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2024, 8, 12]], 'date-time': '2024-08-12T19:33:58Z', 'timestamp': 1723491238000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1876034124002466'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 9]]}, 'references-count': 12, 'journal-issue': {'issue': '9', 'published-print': {'date-parts': [[2024, 9]]}}, 'alternative-id': ['S1876034124002466'], 'URL': 'http://dx.doi.org/10.1016/j.jiph.2024.102512', 'relation': {}, 'ISSN': ['1876-0341'], 'subject': [], 'container-title-short': 'Journal of Infection and Public Health', 'published': {'date-parts': [[2024, 9]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but ' 'remained clinically effective: Were monoclonal antibodies against COVID-19 ' 'rejected too early?', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'Journal of Infection and Public Health', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.jiph.2024.102512', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'simple-article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2024 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin ' 'Abdulaziz University for Health Sciences.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '102512'}